en · de · es · fr · pt
hplc-notes.peptides4800.com › Guide › Ipamorelin Background And Receptor Pharmacology — Beginner to Advanced

Ipamorelin Background And Receptor Pharmacology — Beginner to Advanced

By Editorial Desk · published 2025-09-24 · last reviewed 2025-10-20 · Guide

This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-10-20. Anything still debated is marked as such rather than presented as settled.

Ipamorelin Background and Receptor Pharmacology

In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.

Receptor Selectivity and Secretagogue Signaling

Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.

Ipamorelin at a glance

PropertyValueNotes
Peptide classSynthetic pentapeptideGHS-R1a agonist family
Receptor targetGhrelin receptor (GHS-R1a)G-protein-coupled receptor
Sequence lengthFive amino acid residuesIncludes non-natural residues
Primary reported outputPulsatile growth hormone releaseObserved in animal and early human work
Molecular formulaC38H49N9O5Corresponds to roughly 711.9 g/mol

Background And Receptor Mechanism

Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Related pages on this site

Receptor Mechanism and Secretagogue Action

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

分析检测与储存稳定性

冻干状态下的肽通常比溶液状态更稳定,常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺,速率受 pH、缓冲液种类、离子强度与温度共同影响,碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失,分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程,需与操作条件一并考虑。

对 ipamorelin 的常规表征以反相高效液相色谱测定纯度,检测波长多设为 214 nm,因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱,将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来,可以分别覆盖纯度、身份与序列三个不同层次的信息。

Background and Receptor Selectivity

Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.

Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.

Supporting material

=== Ireland === Nando's was first established in Ireland in 2008. The company opened its flagship restaurant on St Andrew Street in the city centre of Dublin in November 2011, employing 60 staff members to manage a 3,800 square feet (350 m2) space spread over two floors. As of August 2021, they have expanded to a total of 14 outlets in Ireland, with nine in Dublin, two in Cork, one in Newbridge, one in Limerick and one in Galway.

== Cultivation == Cut flower cultivation is intensive, usually on the basis of greenhouse monocultures, and requires large amounts of highly toxic pesticides, residues of which can often still be found in flower shops on imported flowers. As with the production of fruit and vegetables, the industry depends on significant amounts of water, which may be collected and stored by the farm owners. The Patel Dam failure in May 2018, associated with a large Kenyan rose farm, killed dozens of people. These facts have spurred the development of movements like "Slow Flowers", which propagates sustainable floriculture in the consumer country (US, Canada) itself.

In 1905, J. K. Lilly oversaw a large expansion of the company, and it reached annual sales of $1 million. Following the 1906 San Francisco earthquake, the company sent much-needed medicine to support recovery efforts. Before and after World War I, the company experienced rapid growth, including expanded manufacturing facilities at its McCarty Street plant, which improved production capacity with a new Science Building (Building 14), opened in 1911, and a new capsule plant (Building 15) in 1913. In 1913, the company began construction of Lilly Biological Laboratories, a research and manufacturing plant on 150 acres near Greenfield, Indiana. After World War I, the company's expanded production facilities and introduction of new management methods set the stage for Lilly's next crucial phase—its "aggressive entry into scientific research and development." The first big step came in 1919 when Josiah Lilly hired biochemist George Henry Alexander Clowes as director of biochemical research. Clowes had extensive medical research expertise and links to the scientific research community, which led to the company's collaborations with researchers in the US and elsewhere. Clowes's first major collaboration with researchers who developed insulin at the University of Toronto significantly impacted the company's future. Lilly's success with insulin production secured the company's position as a leading research-based pharmaceutical manufacturer, allowing it to attract and hire more research scientists and to collaborate with other universities in additional medical research.

64Cu-ATSM (diacetyl-bis(N4-methylthiosemicarbazone)) has been shown to increase the survival time of tumor-bearing animals. Areas of low oxygen retention have been shown to be resistant to external beam radiotherapy because hypoxia reduces the lethal effects of ionizing radiation. 64Cu was believed to kill these cells because of its unique decay properties. In animal models having colorectal tumors with and without induced hypoxia, Cu-ATSM was preferentially taken up by hypoxic cells over normoxic cells. The results demonstrated that this compound increased survival of the tumor bearing hamsters compared with controls.

At the same time, the volume of fish reaching inland markets such as Sanaʿa reportedly declined by more than half, while retail prices increased by roughly 30–40 percent. This combination of reduced supply and higher prices contributed also to the food insecurity problem. Moreover, the closure or partial shutdown of fish-processing plants, ice factories and related businesses led to thousands of job losses along the chain, with analysts noting how the sector may even experience further shocks, including the possibility of an oil spill in the Red Sea.

Sources: en.wikipedia.org

Notes from published material

He returned in round 7, but had a subsequent dip in form. However, Essendon coach, Matthew Knights, persisted with Jetta and was paid back by his outstanding performance against Fremantle in round 14. The 2009 season was another important year in Jetta's development. A few quiet performances in the pre-season led to his omission from the side for the opening two rounds of the season. However, strong form for the Bendigo Bombers led to a recall for Essendon's vital round 3 encounter with Carlton. On 7 September 2014, Jetta parted ways with Essendon after eight seasons with the club. Jetta, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in February 2017; as a result, he served approximately seventeen months of his suspension and missed the entire 2016 WAFL season and parts of the 2015/16 and 2016/17 NTFL seasons. He later played with Peel Thunder in the WAFL and played for Pinjarra in the WA Amateur Football League in 2018.

In its bark an alkaloid is found which was given the name quebrachine. In 1914, two scientific papers claimed quebrachine was chemically identical to yohimbine. This was disputed, and the matter long remained in doubt. However, in 1972, Effler and Effler using modern analytical techniques, including mass spectrometry, UV absorption, IR absorption, and NMR, established that quebrachine and yohimbine are one and the same thing. They wrote: While it was almost unthinkable in 1914 ... that the same alkaloid was formed in [completely] different plants, recent studies have shown that this is certainly the case for indole alkaloids. The term 'quebrachine' may be used as a synonym for yohimbine. Strictly speaking, wrote George Barger, yohimbine should have been given the scientific name quebrachine, seeing that it was first isolated from the quebracho tree and first named in the scientific literature. However, the later work on P. yohimbe was better known.

Starfish are sometimes eaten in China, Japan, and Palau. Some species, such as the crown-of-thorns starfish, are toxic. Georg Eberhard Rumpf found few starfish being used for food in the Indonesian archipelago, other than as bait in fish traps, but on the island of "Huamobel" [sic], the people cut them up, squeeze out the "black blood" and cook them with sour tamarind leaves; after resting the pieces for a day or two, they remove the outer skin and cook them in coconut milk.

animal shelters boarding facilities (or animals going into them) breeders community cats (free-roaming and/or feral) or TNR (Trap Neuter Return) programs owned pets (and based on "inside only" or "in and out") The FPLV vaccination is considered a "core" (essential for health) vaccine and is recommended for all domestic cats. Even cats kept indoors can be infected from fomite transmission. Several types and brands of commercial FPLV vaccines are available to induce acquired immunity. These include:

Thalassemias are a group of inherited blood disorders that manifest as the production of reduced hemoglobin. Symptoms depend on the type of thalassemia and can vary from none to severe, including death. Often there is mild-to-severe anemia (low red blood cells or hemoglobin), as thalassemia can affect the production of red blood cells and also affect how long the red blood cells live. Symptoms include tiredness, pallor, bone problems, an enlarged spleen, jaundice, pulmonary hypertension, and dark urine. A child's growth and development may be slower than normal. Thalassemias are genetic disorders. Alpha thalassemia is caused by deficient production of the alpha globin component of hemoglobin, while beta thalassemia is a deficiency in the beta globin component. The severity of alpha and beta thalassemia depends on how many of the four genes for alpha globin or two genes for beta globin are faulty. Diagnosis is typically by blood tests including a complete blood count, special hemoglobin tests, and genetic tests. Diagnosis may occur before birth through prenatal testing. Treatment depends on the type and severity. Clinically, thalassemia is classed as Transfusion-Dependent Thalassemia (TDT) or non-Transfusion-Dependent Thalassemia (NTDT), since this determines the principal treatment options. TDT requires regular blood transfusions, typically every two to five weeks. TDTs include beta-thalassemia major, hemoglobin H disease, and severe HbE/beta-thalassemia. NTDT does not need regular transfusions but may require transfusion in case of an anemia crisis.

Sources: en.wikipedia.org

Background from the literature

=== Very long-chain acyl-Coenzyme A dehydrogenase (VLCAD) deficiency === Very long-chain acyl-coenzyme A dehydrogenase deficiency (VLCAD deficiency) is a genetic disorder that affects the body's ability to break down certain fats. In the β-oxidation cycle, VLCAD's role involves the removal of two hydrogen atoms from the acyl-CoA molecule, forming a double bond and converting it into trans-2-enoyl-CoA. This crucial first step in the cycle is essential for the fatty acid to undergo further processing and energy production. When there is a deficiency in VLCAD, the body struggles to effectively break down long-chain fatty acids. This can lead to a buildup of these fats and a shortage of energy, particularly during periods of fasting or increased physical activity. Symptoms

== History == The code name "Looking Glass" came from the aircraft's ability to "mirror" the command and control functions of the underground command post at the U.S. Air Force's Strategic Air Command (SAC) headquarters at Offutt AFB, Nebraska.

Active transport of carbapenem drugs out of the cell, augmented drug efflux, has been observed in some resistant species. One mechanism of resistance is mutation in or loss of outer membrane porins, preventing antibiotics from entering the cells. Changes within the porin protein gene cause a frameshift, altering the porin structure and function. Changes in the porin protein hinder the diffusion of carbapenem and other antibiotics into the periplasm. Bacteria that express plasmid-borne extended-spectrum β-lactamases (ESBL) can become carbapenem-resistant if an insertion sequence or four-nucleotide duplication is present within chromosomal genes for outer membrane porin proteins. Klebsiella pneumoniae has been associated with the lack of outer membrane porin proteins, OmpK35 and OmpK36. The loss of OmpK36 porins can be attributed to point mutations that result in premature termination of translation, resulting in a truncated and consequently nonfunctional protein. These outer membrane proteins are involved in the transfer of the antimicrobial genetic material in the cell. Loss of either OmpK35 and OmpK36 or only OmpK36 leads to carbapenem resistance. In Klebsiella pneumoniae, the lack of either OmpK35 or OmpK36 leads to carbapenem resistance, but with the lack of both proteins, a high level of resistance is present. An observed 32- to 64-fold increase in minimum inhibitory concentrations occurs for the carbapenems when both proteins are not expressed. CRE produce carbapenemases, a form of β-lactamase.

FOXP3 polymorphism (rs3761548) might be involved in cancer progression like gastric cancer through influencing Tregs function and the secretion of immunomodulatory cytokines such as IL-10, IL-35, and TGF-β.

Sources: en.wikipedia.org

Frequently asked questions

What is ipamorelin classified as?

It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.

Does ipamorelin release only growth hormone?

Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.

Is the compound naturally present in the body?

No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.

How does ipamorelin relate to ghrelin?

Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.

Network